<DOC>
	<DOCNO>NCT00255138</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety atomoxetine enhance attention concentration among childhood survivor cancer .</brief_summary>
	<brief_title>Efficacy Atomoxetine Therapy Versus Placebo Cognitive Late Effects</brief_title>
	<detailed_description>In previous year , often assume cognitive behavioral decline child survive cancer therapy largely function prophylactic therapy ( e.g. , radiation , chemotherapy ) child receive . Regardless etiologies specific late effect , data regard long-term outcome child strikingly consistent . Generally , study date suggest significant impairment attention concentration result mark decline academic performance social behavior difficulty . Despite clear evidence problem attention concentration , well associate fucntional impairment ( e.g. , poor academic achievement poor peer relationship ) , clinical trial design manage cogntive late effect neurological toxicity associate radiation therapy chemotherapy child adolescent survive cancer .</detailed_description>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Age 618 Patient receive chemotherapy , radiation , combination . Patient least 12 month postcompetion therapy five year postcompletion therapy . No ongoing pharmacological management ADHD Not currently pregnant</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Cognitive Late Effects</keyword>
	<keyword>Stimulants</keyword>
	<keyword>Atomoxetine</keyword>
	<keyword>Attention</keyword>
	<keyword>Children</keyword>
</DOC>